These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322 [TBL] [Abstract][Full Text] [Related]
29. Human behavioral pharmacology of psychedelics. Strickland JC; Johnson MW Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564 [TBL] [Abstract][Full Text] [Related]
30. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME Clin Pharmacol Ther; 2022 Apr; 111(4):886-895. PubMed ID: 34743319 [TBL] [Abstract][Full Text] [Related]
31. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708 [TBL] [Abstract][Full Text] [Related]
32. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683 [TBL] [Abstract][Full Text] [Related]
33. Response of cluster headache to psilocybin and LSD. Sewell RA; Halpern JH; Pope HG Neurology; 2006 Jun; 66(12):1920-2. PubMed ID: 16801660 [TBL] [Abstract][Full Text] [Related]
34. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Bender D; Hellerstein DJ Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823 [TBL] [Abstract][Full Text] [Related]
35. The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. Hodge AT; Sukpraprut-Braaten S; Narlesky M; Strayhan RC J Psychoactive Drugs; 2023; 55(1):40-50. PubMed ID: 35225726 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Ross S Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082 [TBL] [Abstract][Full Text] [Related]
37. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346 [No Abstract] [Full Text] [Related]
38. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Mikocka-Walus A; Prady SL; Pollok J; Esterman AJ; Gordon AL; Knowles S; Andrews JM Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012680. PubMed ID: 30977111 [TBL] [Abstract][Full Text] [Related]
39. Trial of Psilocybin versus Escitalopram for Depression. Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780 [TBL] [Abstract][Full Text] [Related]
40. Dependence on LSD and other hallucinogenic drugs. JAMA; 1967 Oct; 202(1):141-4. PubMed ID: 6072003 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]